H
Hans Verkerke
Researcher at Emory University
Publications - 39
Citations - 835
Hans Verkerke is an academic researcher from Emory University. The author has contributed to research in topics: Medicine & Antibody. The author has an hindex of 7, co-authored 16 publications receiving 391 citations. Previous affiliations of Hans Verkerke include Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Rapid generation of neutralizing antibody responses in COVID-19 patients
Mehul S. Suthar,Mehul S. Suthar,Matthew G. Zimmerman,Matthew G. Zimmerman,Robert C. Kauffman,Grace Mantus,Susanne L. Linderman,William H. Hudson,Abigail Vanderheiden,Abigail Vanderheiden,Lindsay E. Nyhoff,Carl W. Davis,Oluwaseyi Adekunle,Maurizio Affer,Melanie A. Sherman,Stacian Reynolds,Hans Verkerke,David Alter,Jeannette Guarner,Janetta Bryksin,Michael Horwath,Connie M. Arthur,Natia Saakadze,Geoffrey H. Smith,Srilatha Edupuganti,Erin M. Scherer,Kieffer Hellmeister,Andrew Cheng,Juliet A. Morales,Andrew S. Neish,Sean R. Stowell,Filipp Frank,Eric A. Ortlund,Evan J. Anderson,Vineet D. Menachery,Nadine Rouphael,Aneesh K. Mehta,David S. Stephens,Rafi Ahmed,John D. Roback,Jens Wrammert +40 more
TL;DR: A cross-sectional study of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in a cohort of 44 hospitalized COVID-19 patients, which has implications for understanding protective immunity against SARS-CoV-2, therapeutic use of immune plasma, and development of much-needed vaccines.
Posted ContentDOI
Rapid generation of neutralizing antibody responses in COVID-19 patients.
Mehul S. Suthar,Matthew G. Zimmerman,Robert C. Kauffman,Grace Mantus,Susanne L. Linderman,Abigail Vanderheiden,Lindsay E. Nyhoff,Carl W. Davis,Seyi Adekunle,Maurizio Affer,Melanie A. Sherman,Stacian Reynolds,Hans Verkerke,David Alter,Jeannette Guarner,Janetta Bryksin,Michael Horwath,Connie M. Arthur,Natia Saakadze,Geoffrey H. Smith,Srilatha Edupuganti,Erin M. Scherer,Kieffer Hellmeister,Andrew Cheng,Juliet A. Morales,Andrew S. Neish,Sean R. Stowell,Filipp Frank,Eric A. Ortlund,Evan J. Anderson,Vineet D. Menachery,Nadine Rouphael,Aneesh Metha,David S. Stephens,Rafi Ahmed,John D. Roback,Jens Wrammert +36 more
TL;DR: The dynamics of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in 44 COVID-19 patients revealed the magnitude of RBD-specific IgG binding titers correlated strongly with viral neutralization.
Journal ArticleDOI
The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A.
Shang-Chuen Wu,Connie M. Arthur,Jianmei Wang,Hans Verkerke,Cassandra D. Josephson,Daniel Kalman,John D. Roback,Richard D. Cummings,Sean R. Stowell,Sean R. Stowell +9 more
TL;DR: The RBD of SARS-CoV-2 shares sequence similarity with an ancient lectin family known to bind blood group antigens as mentioned in this paper, which can be used to directly link blood group A and SARS CoV2.
Journal ArticleDOI
Maternal Antibody Response, Neutralizing Potency, and Placental Antibody Transfer After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
Naima T Joseph,Carolynn M. Dude,Hans Verkerke,Les’Shon S. Irby,Anne L. Dunlop,Ravi Mangal Patel,Kirk Easley,Alicia K. Smith,Sean R. Stowell,Denise J. Jamieson,Vijayakumar Velu,Martina L. Badell +11 more
TL;DR: In this article, a prospective cohort study of pregnant patients who tested positive for SARS CoV-2 infection at any point in pregnancy and collected paired maternal and cord blood samples at the time of delivery was conducted to characterize maternal immune response after severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection during pregnancy and quantify the efficiency of transplacental antibody transfer.
Journal ArticleDOI
COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease.
Zahidee Rodriguez,Andi L. Shane,Hans Verkerke,Christopher Lough,Matthew G. Zimmerman,Matthew G. Zimmerman,Mehul S. Suthar,Mehul S. Suthar,Jens Wrammert,Heather MacDonald,Michael Wolf,Shanelle Clarke,John D. Roback,Connie M. Arthur,Sean R. Stowell,Cassandra D. Josephson +15 more
TL;DR: COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir, and infants may benefit from CP despite developing immune systems and donor variability emphasizes the need for characterization prior to use.